BridgeBio Locks $2B Infigratinib Global Partnership For Oncology Indications

At the start of March, BridgeBio Pharma Inc BBIO won approval for its first drug, fosdenopterin, for sporadic cases of molybdenum cofactor deficiency type A.
In the middle of March, it announced positive proof-of-concept data for encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1).
Today, the company is wrapping up the busy month with global collaboration and licensing agreement with Helsinn Group to develop and commercialize infigratinib.
The agreement covers oncology and all other indications except for skeletal dysplasias (including achondroplasia).
Infigratinib is an orally administered ATP-competitive tyrosine kinase inhibitor designed to inhibit FGFR.
Under the terms of the Agreement, BridgeBio will retain all rights to infigratinib in skeletal dysplasia, including achondroplasia.
Subject to FDA approval, BridgeBio Pharma's affiliate QED Therapeutics and Helsinn will co-commercialize infigratinib in oncology indications in the U.S. on a 50:50 basis.
Under the Agreement, BridgeBio will be eligible to receive more than $2 billion in upfront, regulatory and commercial milestones, as well as tiered royalties on adjusted net sales from Helsinn Group.
Helsinn will have exclusive commercialization rights and lead commercialization for infigratinib in non-skeletal dysplasia indications outside of the U.S., excluding China, Hong Kong, and Macau, covered under LianBio collaboration.
Price Action: BBIO shares are up 2.54% at $60.62 in market trading hours on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs

Get The Market's Most Powerful Trading Tools — 50% Off Pro Memorial Day Sale

-

-

-

-

-

-

-

The Market's Most Powerful Trading Tools — 50% OFF Limited Time

-

-

-

-

-

-

-